User:Mr. Ibrahem/Ranibizumab

Ranibizumab, sold under the brand name Lucentis among others, is a medication used to treat "wet" type of age-related macular degeneration (AMD), diabetic retinopathy, macular edema due to retinal vein occlusion, and retinopathy of prematurity. It is given by injection into the eye.

Common side effects include conjunctival bleeding, eye pain, floaters, and increased intraocular pressure. Other side effects may include endophthalmitis and retinal detachment. It is a small piece of monoclonal antibody that attaches to and blocked vascular endothelial growth factor A (VEGF-A).

Ranibizumab was approved for medical use in the United States in 2006 and Europe in 2007. In the United Kingdom it costs the NHS about £550 per dose as of 2021. In the United States it is about 2000 USD per dose.